CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...License and Commercial Supply Agreement • March 30th, 2020 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New Jersey
THIS LICENSE AND COMMERCIAL SUPPLY AGREEMENT (“Agreement”) is made and entered into as of September 2, 2019 (“Effective Date”) by and among Tris Pharma, Inc, with offices at 2033 US Rt 130, Monmouth Jn, NJ 08852 (“Tris”) and Intellipharmaceutics Corp, with offices at 30 Worcester Road, Toronto, ON M9W 5X2, Canada (“IPC”), with respect to the manufacture, supply, sales, licensing and distribution of the generic pharmaceutical Product set forth below. Tris and IPC are sometimes hereafter referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AND COMMERCIAL SUPPLY AGREEMENTLicense and Commercial Supply Agreement • February 28th, 2017 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIAL SUPPLY AGREEMENT (“Agreement”) is made and entered into effective this October 11, 2016 (“Effective Date”) by and between Mallinckrodt LLC, a Delaware limited liability company (for and on behalf of its affiliated entities) (“Mallinckrodt”) and Intellipharmaceutics Corp., a company organized under the laws of Canada (for and on behalf of its affiliated entities) (“Intellipharmaceutics”).
